VLP Therapeutics, LLC.

To help build a sustainable and flexible vaccines ecosystem in Japan after the COVID-19 pandemic, the national Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness

Japan’s Ministry of Health, Labour and Welfare (MHLW) has determined the list of eight types of "important infectious disease" to focus on for domestic development of vaccines. The list, decided by th

Transitioning its current interests in anti-allergy immunotherapy products into a broader R&D effort, UK-headquartered Allergy Therapeutics plc has extended its tie-up with two European biotechs, S

Sanofi/Regeneron End Kevzara Development For COVID-19 Sanofi / Regeneron Pharmaceuticals, Inc. 's interleukin-6 inhibitor Kevzara (sarilumab) will not be developed further for treatment of hospitaliz